BIM
DYN icon

Bogle Investment Management’s Dyne Therapeutics DYN Stock Holding History

Bogle Investment Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,048
Closed -$253K – 36
2020
Q4 		$253K Buy
+12,048
New +$238K 0.4% 123

Other funds holding DYN

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bogle Investment Management's DYN Position: Q1 2021 in Review

Bogle Investment Management sold out of Dyne Therapeutics (DYN) in Q1 2021, closing a stake of 12,048 shares — an estimated $253K sold.

Bogle Investment Management first reported a position in DYN in Q4 2020 and held it in 1 quarter. The position peaked at $253K in Q4 2020. 75 funds tracked by Wall St. Rank hold DYN as of Q1 2021.

  • Bogle Investment Management reported no remaining Dyne Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Bogle Investment Management sold 12,048 Dyne Therapeutics shares in Q1 2021, an estimated $253K.
  • Bogle Investment Management first reported a position in Dyne Therapeutics in Q4 2020 and held it in 1 quarter.
  • Bogle Investment Management's Dyne Therapeutics position peaked at $253K in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2021.

Based on Bogle Investment Management's 13F filing for Q1 2021.